Literature DB >> 9434163

Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.

K B Tan1, J Harrop, M Reddy, P Young, J Terrett, J Emery, G Moore, A Truneh.   

Abstract

A novel (TL1), a recently described (TL2) TNF-like, and three recently described TNF receptor-like (TR1, TR2, TR3) molecules were identified by searching a cDNA database. TL1 and TL2 are type-II membrane proteins. TR2 and TR3 are type-I membrane proteins whereas TR1 appears to be a secreted protein. TL1, TL2, TR2 and TR3 were expressed in hematopoietic cells, whereas TR1 was not. Northern blots hybridized with the cDNA probes revealed multiple forms of RNA as well as inducible expression of TL1, TL2, TR2 and TR3. TL2 and TR3, in particular, were highly induced in activated CD4+ T cells. Radiation hybrid mapping localized TR1 and TL2 to 8q24 and 3q26, respectively, which are not near any known superfamily members. TL1 was mapped to 9q32, near CD30L (9q33) and TR2 and TR3 mapped to the region of chromosome 1 that contains the TNFR-II, 4-1BB, OX40 and CD30 gene cluster at 1p36. Only TR3 in this cluster possesses a death domain. Southern blot analysis revealed the presence of TL and TR genes in different mammalian species. TL2, TR1, TR2 and TR3 were recently described by others as TRAIL/Apo-2L, OPG, HVEM and DR3/WSL-1/Apo-3/TRAMP/LARD, respectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434163     DOI: 10.1016/s0378-1119(97)00509-x

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  63 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.

Authors:  Taylor H Schreiber; Dietlinde Wolf; Matthew S Tsai; Jackie Chirinos; Vadim V Deyev; Louis Gonzalez; Thomas R Malek; Robert B Levy; Eckhard R Podack
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

3.  The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4⁺ and CD8⁺ T-cell immunity.

Authors:  Jason P Twohig; Morgan Marsden; Simone M Cuff; John R Ferdinand; Awen M Gallimore; William V Perks; Aymen Al-Shamkhani; Ian R Humphreys; Eddie C Y Wang
Journal:  FASEB J       Date:  2012-05-16       Impact factor: 5.191

4.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

5.  Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.

Authors:  Alessandra Colombini; Giovanni Lombardi; Emanuela Galliera; Giada Dogliotti; Pietro Randelli; Alexander Meerssemann; Giuseppe Mineo; Paolo Cabitza; Massimiliano Marco Corsi
Journal:  Int Orthop       Date:  2010-07-11       Impact factor: 3.075

Review 6.  Advancement in the research on vascular endothelial growth inhibitor (VEGI).

Authors:  Lijiao Duan; Ganggang Yang; Ruigang Zhang; Lijuan Feng; Cunshuan Xu
Journal:  Target Oncol       Date:  2012-03-03       Impact factor: 4.493

Review 7.  Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Authors:  Noam Jacob; Stephan R Targan; David Q Shih
Journal:  United European Gastroenterol J       Date:  2016-05-10       Impact factor: 4.623

8.  Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Authors:  William V Perks; Ravinder K Singh; Gareth W Jones; Jason P Twohig; Anwen S Williams; Ian R Humphreys; Philip R Taylor; Simon A Jones; Eddie C Y Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

9.  Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function.

Authors:  Xu Chen; Jueheng Wu; Hanning Liu; Zhenjian He; Minghui Gu; Ning Wang; Jianda Ma; Jieping Hu; Lei Xia; Haipeng He; Jie Yuan; Jun Li; Luyuan Li; Mengfeng Li; Xun Zhu
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

10.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.